VE303 for Treatment of Hepatic Encephalopathy (HE)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This research is studying the use of a new drug to learn about its safety and efficacy as a
treatment for hepatic encephalopathy.
Eligible participants will be enrolled and given oral antibiotics followed by 14 days of the
study drug (placebo vs.VE303). There will be visits as well as other procedures to collect
blood and stool samples, and have tests of your cognition (thinking) for this research study.
The hypothesis is that VE303 will safely and effectively improve cognitive function in
patients with a history of overt hepatic encephalopathy.
Phase:
Phase 2
Details
Lead Sponsor:
Patricia Bloom
Collaborators:
American Association for the Study of Liver Diseases American College of Gastroenterology Vedanta Biosciences, Inc.